Skip to main content

Table 1 Baseline demographic and clinical data of the two study groups

From: Regression of cardiac growth in kidney transplant recipients using anti-m-TOR drugs plus RAS blockers: a controlled longitudinal study

 

m-TOR group (n = 30)

Control group (n = 58)

P value

Age (y)

58.2 ± 13.7

54.5 ± 14

0.239

Gender (Male/Female)

21/9

37/21

0.560

Cause of CKD

   

(GN/PKD/HKD/IN/Other)

9/4/1/3/13

23/4/6/9/16

0.370

Time from transplant to study end (mo)

89.7 ± 72

82 ± 30

0.574

Systolic blood pressure (mm Hg)

126 ± 11

130 ± 12

0.122

Diastolic blood pressure (mm Hg)

73 ± 9

76 ± 8

0.129

Serum creatinine (mg/dL)

1.56 ± 0.3

1.5 ± 0.4

0.464

No. of antihypertensive drugs

1.6 ± 1

1.8 ± 0.8

0.224

Hemoglobin (g/dL)

13 ± 1.5

13.6 ± 1.8

0.101

Cholesterol (mg/dL)

177 ± 31

189 ± 40

0.124

Triglycerides (mg/dL)

140 ± 60

165 ± 80

0.103

Uprot (mg/24 h)

275 ± 232

32 ± 47

0.000

BMI (kg/m 2 )

28 ± 4.7

28.3 ± 4.4

0.736

  1. Values are shown as mean ± SD or absolute values. To convert creatinine in mg/dl to μmol/L, multiply by 88.4; Hemoglobin in g/dl to g/L, multiply by 10; cholesterol in mg/dL to mmol/L, multiply by 0.02586; triglycerides in mg/dL to mmol/L, multiply by 0.01129.
  2. Abbreviations: IN, Interstitial nephropathy; CKD, chronic kidney disease; GN, glomerulonephritis; PKD, polycystic kidney disease; HKD, hypertensive kidney disease; IN, interstitial nephropathy; BMI, body mass index; Uprot, daily urinary protein excretion.
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us